---
title: "SPRB.US (SPRB.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/SPRB.US/news.md"
symbol: "SPRB.US"
name: "SPRB.US"
parent: "https://longbridge.com/zh-CN/quote/SPRB.US.md"
datetime: "2026-03-13T01:31:43.047Z"
locales:
  - [en](https://longbridge.com/en/quote/SPRB.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SPRB.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SPRB.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/SPRB.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/SPRB.US/news.md)


# SPRB.US (SPRB.US) — 相关新闻

### [Spruce Biosciences (NASDAQ:SPRB) Announces Quarterly Earnings Results](https://longbridge.com/zh-CN/news/278577738.md)
*2026-03-10T14:56:01.000Z*
> Spruce Biosciences (NASDAQ:SPRB) reported quarterly earnings of ($9.58) per share, missing estimates of ($9.16) by ($0.4

### [](https://longbridge.com/zh-CN/news/278428268.md)
*2026-03-09T16:41:52.000Z*
> Cartesian Therapeutics shares are trading higher after the company reported its Q4 financial results.

### [Spruce hooks a commercial chief to prep for rare disease launch](https://longbridge.com/zh-CN/news/278428213.md)
*2026-03-09T17:21:45.000Z*
> Spruce Biosciences has appointed Dale Hooks as chief commercial officer to lead the launch of its tralesinidase alfa enz

### [Spruce Biosciences 10-K: $0.0M Revenue, $(50.83) EPS on $(39.0) M Net Loss](https://longbridge.com/zh-CN/news/278384128.md)
*2026-03-09T11:35:01.000Z*
> Spruce Biosciences reported $0.0 million in collaboration revenue and a net loss of $39.0 million, or $(50.83) per share

### [Spruce Biosciences Reports Full Year 2025 Financial Results](https://longbridge.com/zh-CN/news/278381798.md)
*2026-03-09T11:24:29.000Z*
### [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/zh-CN/news/278380208.md)
*2026-03-09T11:14:34.000Z*
### [Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates | SPRB Stock News](https://longbridge.com/zh-CN/news/278378913.md)
*2026-03-09T03:05:00.000Z*
> Spruce Biosciences reported its 2025 financial results, highlighting a productive year with key milestones for its TA-ER

### [Spruce Biosciences (SPRB) Projected to Post Quarterly Earnings on Thursday](https://longbridge.com/zh-CN/news/277899310.md)
*2026-03-05T07:59:03.000Z*
> Spruce Biosciences (NASDAQ:SPRB) is set to release its Q4 2025 earnings on March 12, with analysts predicting a loss of 

### [Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference](https://longbridge.com/zh-CN/news/277372951.md)
*2026-03-01T22:37:58.000Z*
> Spruce Biosciences (NASDAQ: SPRB) executives presented at Oppenheimer’s 36th Annual Healthcare and Life Sciences Confere